CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study
10 March 2023. Related: Conference reports, Treatment strategies, Drug resistance.
Conference reports
CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study
10 March 2023. Related: Conference reports, Pregnancy, Paediatric care.
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults
10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.
CROI 2023: Single dose doxycycline as PEP for STIs (DoxyPEP): five studies
10 March 2023. Related: Conference reports, Coinfections and complications.
CROI 2023: Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition?
10 March 2023. Related: Conference reports, mpox (monkeypox).
30th Conference on Retroviruses and Opportunistic Infection (CROI 2023)
1 February 2023. Related: Conference reports.
Glasgow HIV Congress (2022)
1 February 2023. Related: Conference reports.
Glasgow 2022: pipeline studies with bNAbs N6LS and maturation inhibitor GSK254
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: doravirine updates
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: long-acting cabotegravir/rilpivirine: adverse events, implementation and PROMs
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: community statement on HIV and ageing
1 February 2023. Related: Conference reports, Ageing and life expectancy, Treatment advocacy.
Glasgow HIV Congress 2022
1 December 2022. Related: Conference reports.
Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens
1 December 2022. Related: Conference reports, Treatment strategies.
Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK
1 December 2022. Related: Conference reports, Pregnancy.
Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir: QT prolongation and drug-drug interactions
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Mpox updates on epidemiology, treatment and prevention
1 December 2022. Related: Conference reports, mpox (monkeypox).
24th International AIDS Conference (AIDS 2022): Final report
1 December 2022. Related: Conference reports.
IAS 2022: Metabolic complications of newer HIV drugs in older people
1 December 2022. Related: Conference reports, Lipodystrophy and metabolic complications.
14th International Workshop on HIV & Pediatrics
3 October 2022. Related: Conference reports.
First paediatric pharmacokinetic data of dolutegravir in combination with a TAF-based NRTI backbone
3 October 2022. Related: Conference reports, Paediatric care.
24th International AIDS Conference (AIDS 2022): further reports
3 October 2022. Related: Conference reports.
AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3
3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
AIDS 2022: Gender-affirming hormones, weight gain and ART
3 October 2022. Related: Conference reports, PK and drug interactions, Side effects.
24th International AIDS Conference (AIDS 2022)
1 September 2022. Related: Conference reports.
Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study
1 September 2022. Related: Conference reports, Pregnancy.
Weight gain with dolutegravir and TAF in ADVANCE study continues out to week 192
1 September 2022. Related: Conference reports, Women's health.
VRC01 added to early ART in infants did not reduce viral reservoir
1 September 2022. Related: Conference reports, Paediatric care.
Using PrEP during pregnancy is safe for children
1 September 2022. Related: Conference reports, Pregnancy, Paediatric care.
Long-acting CAB/RPV injections have a similar weight and lipid profile to dolutegravir-based oral ART
1 September 2022. Related: Conference reports.
Montreal’s response to monkeypox: rapid vaccine rollout, 39 breakthrough infections
1 September 2022. Related: Conference reports, mpox (monkeypox).
Summary of 620 cases of monkeypox seen at three London clinics
1 September 2022. Related: Conference reports, mpox (monkeypox).
Advances in HIV cure-related research: IAS workshop now online
1 September 2022. Related: Conference reports.
24th International AIDS Conference (AIDS 2022): first reports
3 August 2022. Related: Conference reports.
Dolutegravir-based ART in children and adolescents: effective in six African countries
3 August 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Early data on injecting CAB/RPV-LA into thigh muscle
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Simplifed lenacapavir dosing: PK results in HIV negative study
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Doxycycline PEP significantly reduces STIs in people at high risk of infections
3 August 2022. Related: Conference reports, Coinfections and complications.
Another possible HIV cure case after stem cell transplantation for cancer; example of extended post-treatment control in Spain
3 August 2022. Related: Conference reports, Cure-related research.
Other cure-related sessions at AIDS 2022
3 August 2022. Related: Conference reports, Cure-related research.
Selected reports launched at AIDS 2022
3 August 2022. Related: Conference reports, On the web.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): final report
1 July 2022. Related: Conference reports.
CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results
1 July 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): further reports
1 June 2022. Related: Conference reports.
CROI 2022: Updates from the VESTED study
1 June 2022. Related: Conference reports, Treatment strategies.
CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART
1 June 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
2 May 2022. Related: Conference reports.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
CROI 2022: Other COVID-19 studies
2 May 2022. Related: Conference reports, Coinfections and complications, COVID-19.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports
1 April 2022. Related: Conference reports.
CROI 2022: Webcasts now online and open access
1 April 2022. Related: Conference reports.
CROI 2022: Islatravir studies for HIV treatment and PrEP
1 April 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses
1 April 2022. Related: Conference reports, Coinfections and complications, COVID-19: long COVID, COVID-19.
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART in the REPRIEVE study
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: UK study shows PEP is started earlier using home starter packs
1 April 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Summary of 14 key studies on HIV and liver disease
1 April 2022. Related: Conference reports, Hepatitis coinfection.
CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs
1 April 2022. Related: Conference reports, Cure-related research.
29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports
1 March 2022. Related: Conference reports.
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
1 March 2022. Related: Conference reports, Antiretrovirals.